Equity · Healthcare
APGE
Apogee Therapeutics, Inc. · NasdaqGM
The line runs $81 on 20 May through $134.59 on 17 August, on a scale from $60 to $140. Days the market did not trade hold the previous close, flat.
The chart above plots the price of APGE over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $81 on 20 May 2026 through $134.59 on 17 August 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026
APGE insider trades
APGE has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 10 December 2025.
Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
APGE reported financials
APGE reported net income of −$255.8M for the fiscal year ended 31 Dec 2025.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
APGE earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
APGE institutional holders
13 of the 45 institutional funds we track reported a APGE position for the quarter ended 30 Jun 2026 — a combined $641.6M; the latest of those filings landed 14 Aug 2026.
Showing the 10 largest of 13 reported positions. The figures above count all of them.
Source: SEC EDGAR 13F filings
APGE fails-to-deliver
On 30 Jul 2026, 3,718 shares of APGE failed to deliver (about $499K) — the latest of 2 consecutive trading days with recorded fails.
Source: SEC fails-to-deliver (CNS) data